... from any ideas, methods, instructions or products referred to in the content or advertisements. 2021 Early breast cancer Neoadjuvant systemic therapy Adjuvant treatment Endocrine therapy Chemotherapy Breast surgery Axillary surgery Radiotherapy Immunotherapy Survivorship Consensus...

... in metastatic, neoadjuvant, and adjuvant settings of HER2-positive breast cancer. Breast cancer Checkpoint inhibitor Immunotherapy HER2-positive breast cancer Clinical trials Systematic review Atezolizumab is explored in 8 clinical trials, pembrolizumab in 2 clinical trials, durvalumab in 2...

... as cellular therapies (adoptive cell therapy and chimeric antigen receptor T cells). Key Messages: Immunotherapy is an emerging modality for the treatment of breast cancer, as evidenced by the plethora of preclinical and clinical concepts and ongoing trials. Early studies established the role...

... responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Liquid biopsy Immuno-oncology Immunotherapy Immune checkpoints Immune checkpoint inhibitors Breast cancer Gynecological cancer...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Programmed death-1 protein (PD-1) PD-L1 Checkpoint therapy Immunotherapy Breast cancer Triple negative breast cancer TNBC Immune cells Review Article Breast Care...

..., instructions or products referred to in the content or advertisements. Breast cancer Immunotherapy Natural killer cells Tumor-associated macrophages Tumor microenvironment Breast carcinoma is the most common malignant disease in the female population and one of the leading causes of death among...

...-term survival after pembrolizumab monotherapy. Conclusion: Immunotherapy is emerging as a promising treatment for some breast cancer patients. Nevertheless, monotherapy studies have shown a very limited activity. Nowadays, there is no good predictor biomarker. Further investigations are needed...

...Florian Schütz; Frederik Marmé; Christoph Domschke; Christof Sohn; Alexandra von Au Summary Immunotherapies are set to become part of the therapeutic repertoire for breast cancer in the near future. Active vaccination is a promising strategy, especially in tumors that have a specific tumor...

..., instructions or products referred to in the content or advertisements. 2017 Triple-negative breast cancer Genomics Molecular subtypes BRCA Immunotherapy Cytotoxic chemotherapy Triple-negative breast cancer (TNBC) is defined as lacking the expression of estrogen receptor (ER), progesterone...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2016 Breast cancer Immunotherapy...

...Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz Summary More recently, immunotherapy has emerged as a novel potentially effective therapeutic option also for solid malignancies such as breast...

... inhibition in breast cancer by reviewing in detail data on PD-L1 expression and its regulation. In addition, opportunities to boost anti-tumor immunity in breast cancer with checkpoint inhibitor-based immunotherapies alone and in combination with other treatment options will be discussed. A transcriptomic...

... Unit 981, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France cBreast Cancer Translational Research Laboratory (BCTL), Institut Jules Bordet, Brussels, Belgium Keywords Breast cancer · Tumor-infiltrating lymphocytes · Prognosis · Immunotherapy Schlüsselwörter Brustkrebs...